JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Kodu・Aktsiate loetelu・AbCellera Biologics Inc

AbCellera Biologics Inc

Suletud

SektorTervishoid

5.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.66

Max

5.76

Põhinäitajad
By Trading Economics
Sissetulek	11M -35M
Müük	13M 17M
Kasumimarginaal	-203.272
Töötajad	596
EBITDA	769K -39M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+62.54% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	456M 1.8B
Eelmine avamishind	5.67
Eelmine sulgemishind	5.67

Uudiste sentiment

By Acuity

60%

40%

309 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. okt 2025, 18:41 UTC

Tulu

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. okt 2025, 18:31 UTC

Tulu

Correction to Procter & Gamble to Focus on Innovation

24. okt 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. okt 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. okt 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. okt 2025, 21:07 UTC

Tulu

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. okt 2025, 20:58 UTC

Tulu

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 20:40 UTC

Tulu

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. okt 2025, 20:24 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:23 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:13 UTC

Tulu

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. okt 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. okt 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. okt 2025, 19:33 UTC

Tulu

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. okt 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. okt 2025, 18:52 UTC

Tulu

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:41 UTC

Tulu

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:03 UTC

Tulu

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. okt 2025, 18:02 UTC

Tulu

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. okt 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. okt 2025, 16:57 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. okt 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. okt 2025, 16:44 UTC

Market Talk

Tulu

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. okt 2025, 16:39 UTC

Market Talk

Tulu

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. okt 2025, 16:33 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:23 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 16:07 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

62.54% tõus

12 kuu keskmine prognoos

Keskmine 9.2 USD 62.54%

Kõrge 17 USD

Madal 5 USD

Põhineb 7 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

309 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.